2022
Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Peng S, Ying A, Chan N, Sundar R, Soon Y, Bandla A. Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Frontiers In Oncology 2022, 12: 731223. PMID: 35186722, PMCID: PMC8853097, DOI: 10.3389/fonc.2022.731223.Peer-Reviewed Original ResearchOxaliplatin-induced peripheral neuropathyNon-pharmacological interventionsChronic oxaliplatin-induced peripheral neuropathyMeta-analysisSystematic reviewPrevent oxaliplatin-induced peripheral neuropathyGrading of RecommendationsPreventive measuresPooled risk ratioQuality of lifeRandomized controlled trialsPrimary outcome measureRandom-effects modelDatabases PubMed-MEDLINENetwork meta-analysisPreventive interventionsOutcome measuresNo interventionPubMed-MedlinePeripheral neuropathyClinical impactRisk ratioControlled trialsCancer patientsConfidence intervals
2021
Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial
Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.Peer-Reviewed Original ResearchTumor marker levelsRandomized controlled trialsChemotherapy doseSolid tumorsDrug doseDosing recommendationsMarker levelsAmerican Association for Cancer Research annual meetingsSignificant dose changesTumor marker measurementsCapecitabine-based chemotherapyMetastatic solid tumorsOptimal chemotherapy dosingRecruitment of patientsFrequent toxicitiesOpen-labelCA19-9Dose changesCohort expansionTumor markersSingle-armSuboptimal efficacyProportion of participantsChemotherapySerial measurements
2020
Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review
Cheong C, Nistala K, Ng C, Syn N, Chang H, Sundar R, Yang S, Chong C. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. Journal Of Gastrointestinal Oncology 2020, 11: 847-857. PMID: 33209481, PMCID: PMC7657836, DOI: 10.21037/jgo-20-220.Peer-Reviewed Original ResearchLocally advanced colon cancerAdvanced colon cancerR0 resection rateDisease-free survivalNeoadjuvant chemotherapyColon cancerNeoadjuvant therapyRandomized controlled trialsOverall survivalResection rateAdjuvant chemotherapyChina Knowledge Resource Integrated DatabaseSurvival benefit of neoadjuvant chemotherapyBenefit of neoadjuvant chemotherapyRisk of peri-operative complicationsObservational studyObservational study of patientsAdverse effects of chemotherapyPeri-operative complicationsPotential survival benefitMeta-analysisEffects of chemotherapyStudy of patientsFOxTROT trialUpfront operation